Literature DB >> 22977160

Mutations selected in HIV-2-infected patients failing a regimen including atazanavir.

Joana Cavaco-Silva1, Maria João Aleixo, Kristel Van Laethem, Domitília Faria, Emília Valadas, Maria de Fátima Gonçalves, Perpétua Gomes, Anne-Mieke Vandamme, Celso Cunha, Ricardo Jorge Camacho.   

Abstract

OBJECTIVES: To investigate mutations selected in viruses from HIV-2-infected patients failing a highly active antiretroviral treatment (HAART) regimen including atazanavir/ritonavir.
METHODS: Twenty-eight HIV-2-infected patients previously exposed to atazanavir/ritonavir and failing therapy were studied. The protease (PR) gene was amplified and sequenced, and mutations emerging under atazanavir/ritonavir selective pressure were reported.
RESULTS: The I50L mutation emerged in 4 out of 28 HIV-2-infected patients failing a HAART regimen including atazanavir/ritonavir. Besides I50L, four PR mutations previously associated with protease inhibitor resistance (I54L, I64V, V71I and I82F) and six PR mutations of unknown impact (V10I, E37D, S43T, K45R, I75V and F85L) in HIV-2 were also identified in this small group of patients.
CONCLUSIONS: Several mutations were associated with virological failure of a regimen including atazanavir/ritonavir in HIV-2-infected patients, including I50L for the first time. It should be included in HIV-2 algorithms for interpretation of genotypic resistance data, and taken into account when making therapeutic decisions for HIV-2-infected patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22977160     DOI: 10.1093/jac/dks363

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy.

Authors:  Dana N Raugi; Robert A Smith; Selly Ba; Macoumba Toure; Fatou Traore; Fatima Sall; Charlotte Pan; Lindsey Blankenship; Alexandra Montano; Julia Olson; Ndeye Mery Dia Badiane; James I Mullins; Nancy B Kiviat; Stephen E Hawes; Papa Salif Sow; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

2.  Assessment of the Cavidi ExaVir Load Assay for Monitoring Plasma Viral Load in HIV-2-Infected Patients.

Authors:  Pedro Borrego; Maria Fátima Gonçalves; Perpétua Gomes; Lavínia Araújo; Inês Moranguinho; Inês Brito Figueiredo; Isabel Barahona; José Rocha; Claudino Mendonça; Maria Cesarina Cruz; Jorge Barreto; Nuno Taveira
Journal:  J Clin Microbiol       Date:  2017-05-17       Impact factor: 5.948

3.  Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2.

Authors:  Philip L Tzou; Diane Descamps; Soo-Yon Rhee; Dana N Raugi; Charlotte Charpentier; Nuno Taveira; Robert A Smith; Vicente Soriano; Carmen de Mendoza; Susan P Holmes; Geoffrey S Gottlieb; Robert W Shafer
Journal:  J Infect Dis       Date:  2020-06-11       Impact factor: 5.226

4.  Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide Sensitivity to Protease Inhibitors.

Authors:  Dana N Raugi; Robert A Smith; Geoffrey S Gottlieb
Journal:  J Virol       Date:  2015-11-11       Impact factor: 5.103

5.  Long-term Experience and Outcomes of Programmatic Antiretroviral Therapy for Human Immunodeficiency Virus Type 2 Infection in Senegal, West Africa.

Authors:  Dana N Raugi; Selly Ba; Ousseynou Cisse; Khardiata Diallo; Ibrahima Tito Tamba; Cheikh Ndour; Ndeye Mery Dia Badiane; Louise Fortes; Mouhamadou Baïla Diallo; Dominique Faye; Robert A Smith; Fatima Sall; Macoumba Toure; ElHadji Ibrahima Sall; Habibatou Diallo Agne; Khadim Faye; Jean Philippe Diatta; Marie Pierre Sy; Ming Chang; Binetou Diaw; Jacques Sambou; Raphael Bakhoum; Mame Demba Sy; Alassane Niang; Jean Jacques Malomar; Robert W Coombs; Stephen E Hawes; Ibra Ndoye; Nancy B Kiviat; Papa Salif Sow; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Clin Infect Dis       Date:  2021-02-01       Impact factor: 20.999

6.  Plasma HIV-2 RNA According to CD4 Count Strata among HIV-2-Infected Adults in the IeDEA West Africa Collaboration.

Authors:  Didier K Ekouévi; Véronique Avettand-Fènoël; Boris K Tchounga; Patrick A Coffie; Adrien Sawadogo; Daouda Minta; Albert Minga; Serge P Eholie; Jean-Christophe Plantier; Florence Damond; François Dabis; Christine Rouzioux
Journal:  PLoS One       Date:  2015-06-25       Impact factor: 3.240

7.  Impacts of drug resistance mutations on the structural asymmetry of the HIV-2 protease.

Authors:  Pierre Laville; Sandrine Fartek; Natacha Cerisier; Delphine Flatters; Michel Petitjean; Leslie Regad
Journal:  BMC Mol Cell Biol       Date:  2020-06-23

8.  [HIV-2 infection in Senegal: virological failures and resistance to antiretroviral drugs (ARVs)].

Authors:  Selly Ba; Ndeye Mery Dia-Badiane; Stephen Edward Hawes; Louise Fortes Deguenonvo; Fatima Sall; Cheikh Tidiane Ndour; Khadim Faye; Fatou Traoré; Macoumba Touré; Marie Pierre Sy; Dana Noelle Raugi; Nancy Berenice Kiviat; Robert Alexander Smith; Moussa Seydi; Papa Salif Sow; Geoffrey Scott Gottlieb
Journal:  Pan Afr Med J       Date:  2019-07-18

9.  Structural Impacts of Drug-Resistance Mutations Appearing in HIV-2 Protease.

Authors:  Pierre Laville; Michel Petitjean; Leslie Regad
Journal:  Molecules       Date:  2021-01-25       Impact factor: 4.411

10.  Exploration of the effect of sequence variations located inside the binding pocket of HIV-1 and HIV-2 proteases.

Authors:  Dhoha Triki; Telli Billot; Benoit Visseaux; Diane Descamps; Delphine Flatters; Anne-Claude Camproux; Leslie Regad
Journal:  Sci Rep       Date:  2018-04-10       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.